Gilenya in Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

May 31, 2015

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Gilenya

0.5mg Gilenya orally by mouth once daily for approximately 28 days

OTHER

Placebo

0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days

Trial Locations (4)

30912

Georgia Regents University, Augusta

77030

Methodist Neurological Institute, Houston

92868

University of California, Irvine, Orange

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

ALS Therapy Development Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT01786174 - Gilenya in Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter